Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Intermediate Capital Group","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eliem Raises $60M to Take Neuro Programs to Series of Data Drops","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Castle Creek, Eliem and Adagio file for IPOs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Therapeutics Provides ETX-810 Program Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Therapeutics Provides Update on Pipeline Progress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Eliem Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Eliem Therapeutics

    Menu

    Eliem Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eliem Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

              Details:

              The net proceeds will be used for the development of TNT119 (budoprutug), a best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy.

              Lead Product(s): Budoprutug

              Therapeutic Area: Immunology Product Name: TNT119

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: RA Capital Management

              Deal Size: $120.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement April 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eliem Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

              Details:

              The combined company will focus on clinical development of lead product candidate, TNT119 (budoprutug), a best-in class anti-CD19 antibody, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia.

              Lead Product(s): Budoprutug

              Therapeutic Area: Immunology Product Name: TNT119

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Tenet Medicines

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition April 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eliem Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eliem Therapeutics Provides Update on Pipeline Progress

              Details:

              ETX-155 is a novel GABAA receptor positive allosteric modulator (GABAA PAM) that is being developed for the treatment of major depressive disorder (MDD) and epilepsy.

              Lead Product(s): ETX-155

              Therapeutic Area: Psychiatry/Psychology Product Name: ETX-155

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eliem Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eliem Therapeutics Provides ETX-810 Program Update

              Details:

              In Phase 2a trial in LSRP, ETX-810 (ETX-018810) did not achieve statistically significant separation from placebo on trial’s primary endpoint, which assessed change from baseline to week 4 in average of daily pain score measured with Pain Intensity Numerical Rating Scale.

              Lead Product(s): ETX-018810

              Therapeutic Area: Neurology Product Name: ETX-810

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eliem Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

              Details:

              ETX-155 is an investigational oral, next generation, neuroactive steroid NCE that acts as a GABAA positive allosteric modulator (PAM) designed to address the shortcomings of other molecules targeting the GABAA channel.

              Lead Product(s): ETX-155

              Therapeutic Area: Psychiatry/Psychology Product Name: ETX-155

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eliem Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

              Details:

              In Phase 2a clinical trial in DPNP, ETX-810 did not achieve statistically significant separation from placebo on trial’s primary endpoint, which assessed change from baseline to week 4 in weekly average of daily pain score measured with Pain Intensity Numerical Rating Scale.

              Lead Product(s): ETX-810

              Therapeutic Area: Neurology Product Name: ETX-810

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eliem Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Castle Creek, Eliem and Adagio file for IPOs

              Details:

              ETX-810 and ETX-155, ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSR, commonly referred to as sciatica).

              Lead Product(s): ETX-810

              Therapeutic Area: Neurology Product Name: ETX-018810

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Public Offering July 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eliem Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eliem Raises $60M to Take Neuro Programs to Series of Data Drops

              Details:

              Eliem plans to use the proceeds to advance its two lead clinical-stage product candidates, ETX-810 and ETX-155, across four different indications in patients with chronic pain, depressive disorders, and epilepsy, as well as two preclinical-stage programs.

              Lead Product(s): ETX-810

              Therapeutic Area: Neurology Product Name: ETX-810

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Intermediate Capital Group

              Deal Size: $60.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing May 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY